Intensity modulated radiotherapy might be effective for locally advanced esophageal carcinosarcoma
A single center’s experience and review of literature

Siran Yang, MD,a,b‡, Wening Wang, MD,a Nan Bi, MD, PhD,a,#, Zongmei Zhou, MD,a, Qinfu Feng, MD,a, Zefen Xiao, MD,a, Dongfu Chen, MD,a, Jun Liang, MD,a, Jima Lu, MD,a, Jianyang Wang, MD,a, Xin Wang, MD,a, Jingbo Wang, MD,a, Yong Yang, MD,a, Ningning Lu, MD,a, Hongxing Zhang, MD,a, Luhua Wang, MD,a

Abstract
Esophageal carcinosarcoma is a rare type of esophageal cancer; however, few studies have investigated the effects of radiotherapy in locally advanced patients. This study aimed to report experience of the safety and efficacy of intensity-modulated radiotherapy for locally advanced esophageal carcinosarcoma and review the literature. By searching the institutional database between January 2010 and December 2020, along with the literature review, 25 patients were eligible for the study. The clinical and radiologic information of all patients with esophageal carcinosarcoma who underwent radiotherapy were collected. Survival outcomes were calculated using Kaplan–Meier plots. In our series, 5 patients were in the curative/neoadjuvant radiotherapy group and 10 patients were in the adjuvant group. Most tumors were protruding (n = 10, 66.7%). All patients underwent intensity-modulated radiotherapy. In the curative/neoadjuvant radiotherapy group, 2 patients underwent concurrent chemoradiotherapy before surgery, and the other three received radiotherapy alone as the initial treatment. The median follow-up time was 43.1 months. All patients showed a partial response at the efficacy evaluation. The median time of overall survival and progression-free survival were 40.2 months (95% confidence interval [CI], 13.1–67.3 months) and 19.0 months (95% CI, 13.9 months–24.1 months) for the entire cohort, but were not reached for curative/neoadjuvant radiotherapy group. Overall survival (hazard ratio [HR] 0.81, 95% CI, 0.15–4.43; \( P =.805 \)) and progression-free survival (HR 1.68, 95% CI, 0.35–8.19; \( P =.514 \)) did not differ significantly between the 2 groups. When considering the literature review data in the final analysis, overall survival (HR 0.84, 95% CI, 0.26–1.76; \( P =.425 \)) was also not different between the 2 groups. Treatment based on intensity-modulated radiotherapy with neoadjuvant or curative intent may be an option for patients with unresectable esophageal carcinosarcoma. Further research with a larger sample size is needed to validate the reliability.

Abbreviations: CRT = chemoradiotherapy, CI = confidence interval, EC = esophageal cancer, ECS = esophageal carcinosarcoma, HR = hazard ratio, IMRT = intensity-modulated technique radiotherapy, OS = overall survival, PFS = progression-free survival, RT = radiation therapy.

Keywords: curative radiotherapy, intensity modulated radiotherapy, locally advanced esophageal carcinosarcoma, neoadjuvant radiotherapy, survival

1. Introduction
Esophageal cancer (EC) mainly includes esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESCC), and ranks seventh and sixth with respect to tumor incidence and total tumor mortality worldwide (1); the corresponding numbers are all sixth in China according to the most recent national research (2). Carcinosarcoma is a rare malignant tumor that was first proposed in the middle of the 19th century (3) and occurs in different types of organs. Esophageal carcinosarcoma (ECS) is a rare malignant neoplasm that consists of both carcinomatous and sarcomatous components. It reportedly accounts for 0.5%
to 2.8% of all EC.[4] Multiple designations such as carcinosarcoma and pseudo-sarcoma have been assigned to this neoplastic disorder, which reflects the different views regarding the heterogeneity of histogenesis and biology, as well as whether the spindle cell component is epithelial or mesenchymal in origin.[5]

Radical esophagectomy with adequate lymph node dissection is the standard treatment for ECS. However, for locally advanced potentially operable or inoperable patients, the efficacy of neoadjuvant or curative radiation therapy (RT) remains controversial because of the rather limited number of cases and difficulty in implementing a prospective trial. Few studies have reported the clinical treatment and outcome, most of which were case reports, retrospectively evaluated local medical databases in the early years to analyze cases diagnosed with ECS receiving RT as treatment with curative intent.[6-8] A total of 10 patients (6 men and 4 women) were reported. To date, the sensitivity of malignancies towards radiation and the containment of toxicities have not been proven in the era of intensity-modulated techniques.

Owing to the limited number of published cases, there is insufficient epidemiological evidence for the safety and effectiveness of neoadjuvant or definitive RT in ECS. With a case series and an overview of the literature, we increased the number of published cases and aimed to broaden the clinical knowledge on ECS and the possible role of neoadjuvant or definitive RT for patients with locally advanced ECS, and compared the clinical outcomes with the regimen of surgery combined with adjuvant RT. Here, we describe the experience of patients with ECS who received intensity-modulated radiotherapy (IMRT) or chemoradiotherapy (CRT) at our institution in the recent decade and summarize the existing literature.

2. Patients and methods

2.1. Patient eligibility and evaluation

From 2010 to 2020, we analyzed patients diagnosed with EC and enrolled patients pathologically confirmed with ECS. Data were retrospectively assessed from the institutional review board-approved databases: demographic characteristics, diagnosis (i.e., symptoms, workup, biopsy histology), treatment (curative treatment, neoadjuvant treatment, details of surgical resection, and adjuvant therapies), pathological results (type, quality of resection, involvement of lymph nodes), according to the American Joint Committee on Cancer (AJCC)/International Union against Cancer (UICC) TNM staging 8th edition, and long-term follow-up. Neoadjuvant treatment response was evaluated using the Mandard tumor regression grade (TRG).[9]

The literature study was performed in PubMed and Google Scholar with the following search terms: “neoadjuvant”/“curative”/“definitive,” “radiotherapy”/“radiation therapy,” and “chemoradiotherapy” in combination with “Esophageal carcinosarcoma,” “Esophageal carcinoma,” “Esophageal sarcoma,” “Esophageal spindle cell carcinoma,” “Esophageal squamous cell carcinoma,” “Esophageal adenocarcinoma,” “Esophageal cancer,” and “complication,” “toxicity,” “side-effects,” and “survival”. In our overview of the literature (Table 1), we present all the papers published to date, with cases concerning ECS receiving neoadjuvant or curative RT (one patient without survival outcome). Because of the limited number of papers published on this topic, apart from the patients who received surgery combined with adjuvant RT, which was used to compare survival outcomes, there were no other inclusion criteria for the selection of the literature. The sources and methods of selection of participants were showed in flow chart (Fig. 1). The results of the literature search are summarized in tabular form.

### Table 1

| Author           | Case         | Clinical stage | Treatments                                      | Regimens                      | Pathological stage | Response* | PFS            | OS            |
|------------------|--------------|----------------|-------------------------------------------------|-------------------------------|--------------------|-----------|----------------|---------------|
| Zulki et al, 2009 | 50 YO, M     | III (cT1b-3N1M0) | CRT + surgery                                   | FP + 40 Gy                    | II (pT1bN1M0)      | PR        | 36 mo recurrence | 36 mo alive   |
| Zulki et al, 2009 | 66 YO, M     | I (cT1b-N0M0)   | CCRT + surgery                                  | FP + 40.8 Gy                  | I (pT1N0M0)        | PR        | 11 mo recurrence  | 19 mo alive   |
| Kobayashi et al, 2010 | 64 YO, M   | II (cT1-2N1M0)  | CCRT + surgery                                  | FP + 38 Gy                    | II (pT1aN1M0)      | 2         | 4 mo metastasis  | 11 mo dead    |
| Lokesh et al, 2010 | 55 YO, F     | -               | RT alone                                        | 66Gy/3 Gy per fraction for 2 wks followed by 2 Gy per fraction for 3 wks | -                  | CR        | 24 mo free of disease | 24 mo disease-free alive |
| Cavallin et al, 2010 | 50 YO, M    | I (cT1N0M0)     | NeoadjuvantCRT + surgery + RT + surgery + adj RT | CRT                           | RT + surgery       | 40 G      | 0 (pT1aN0M0)    | 14 mo metastasis | 16 mo dead    |
| Ogasaavara et al, 2014 | 69 YO, M | I (cT1b-N0M0)   | CRT                                           | CRT                           | CRT               | TS-1+66 G | PR             | 3 mo alive     |
| Nakao et al, 2015 | 87 YO, M     | I (cT1b-2N0M0)  | CRT                                           | CRT                           | CRT               | TS-1+66 G | PR             | 3 mo alive     |
| Katsuya et al, 2017 | 67 YO, F     | II (cT1b-N1M0)  | CCRT + surgery                                  | FP + 50.4 Gy                  | I (pT1N0M0)        | 1         | 4.5 mo free of disease | 10.9 mo dead  |
| Katsuya et al, 2017 | 73 YO, F     | III (cT1-2N0M0) | CCRT + surgery                                  | FP + 41.4 Gy                  | I (pT1N0M0)        | 2         | 47 mo recurrence | 47 mo alive    |
| Kimura et al, 2019 | 89 YO, M     | II (cT1-2N0M0)  | RT alone                                       | 45 Gy/15f                     | -                  | CR        | 25 mo free of disease | 25 mo disease-free alive |

**CRT = chemoradiotherapy, CCRT = concurrent chemoradiotherapy, CR = complete response, F = female, FP = cisplatin+5-fluorouracil, M = male, NA = not available, OS = overall survival, PFS = progression-free survival, PR = partial response, RT = radiation therapy, TS-1 = tegafur, YO = years old.**

*Pathological response: 0, No evidence of effect; 1, Viable tumor cells occupy more than 1/3 of the tumorous area; 2, Viable tumor cells remain in less than 1/3 of the tumorous area.
lesion) or tumor bed, with mediastinal and supra/infracavicular lymph nodal area, and margin for planning target volume (PTV) was recommended as 1 cm superior-inferiorly and 0.5 to 0.7 cm in the other directions. The irradiation was delivered using inverse- or forward-planned (field-in-field) IMRT, with the prescribed dose covering 95% of the PTV.

2.3. Endpoints
The primary endpoint was local recurrence (PFS), defined as disease recurrence or newly diagnosed metastasis in the primary location and/or regional lymph nodes, or death due to any cause, whichever occurred first. The secondary endpoints were overall survival (OS) and toxicities. OS events included death from any cause.

Acute toxicity was assessed and scaled during and after treatment according to the Common Terminology Criteria for Adverse Events version 4.03. Late toxicity was assessed using NRG-Radiation Therapy Oncology Group criteria.

2.4. Statistical analysis
Categorical variables are expressed as frequencies, and continuous variables are expressed as maximum, minimum, and median values. Patient characteristics were compared using the chi-square test or Fisher exact test for categorical variables and Wilcoxon or Kruskal–Wallis H rank-sum test of variance for continuous data. Survival was calculated as the number of months from surgery to death or last follow-up visit for all patients. As no surgical treatment was performed, the time interval was calculated from the date of diagnosis. Categorical data are expressed as number and percentage, and continuous data are expressed as median and interquartile range (IQR). OS and PFS were calculated using the Kaplan–Meier plots. Patients with missing data were included in the study. All analyses were performed using SPSS version 26.0 (IBM Corporation, Armonk, NY) and R version 4.1.0 (The R Foundation for Statistical Computing, Vienna, Austria).

The authors are accountable for all aspects of the work, ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. This study was conducted in accordance with the Declaration of Helsinki (revised in 2013). This study was approved by the institutional ethics committee, and the requirement for individual consent was waived. Written informed consent was obtained from all subjects involved in the study. The need for ethical approval was waived for this study because of its retrospective nature.

3. Results
3.1. Patient characteristics
Of the 11,682 patients diagnosed with EC at our institution, 64 (0.5%) were pathologically confirmed to have ECS. RT was performed in 15 patients, with 10 patients who underwent
adjuvant RT (adjuvant RT group) and 5 patients who under-
went neoadjuvant or curative RT (curative/neoadjuvant RT 
group; Fig. 1). All 15 patients were men. The median age at 
diagnosis was 55 years (range: 39–70 years). The majority 
of tumors were located in the middle third (n = 10, 66.7%) of 
the esophagus, and 3 (20.0%) and 2 (13.3%) were located 
in the upper and lower thirds of the esophagus, respectively. 
As shown in Figure 2, the protruding type was the most com-
mon endoscopic type (n = 10; 66.7%). Near-or full-peripheral 
lesions were observed in most patients (n = 14, 93.3%). The 
endoscopic appearance also showed superficial erosion of 
the ulcerative lesion, which bled easily when touched. Esophageal 
ultrasound endoscopy revealed that the lesions were mostly 
moderate-to-hypoechoic, the internal echo was uneven, and 
the boundary was unclear. The depth of infiltration exceeded 
the fibrous membrane and reached peripheral structure invasion in 
only 2 patients (13.3%), while others were confined to the sub-
mucosa or muscularis propria layer or only involved fibrous 
membrane. X-ray barium meal revealed broken mucosal 
folds, niches, and limited filling defects. Computed tomogra-
phy (CT) revealed irregular thickening of the esophageal wall 
and uneven enhancement. The median length of the focus was 
6.0 (range: 4–11 cm). Mediastinal, supraclavicular, or cardia 
lymph node metastases were observed in most patients (n = 14, 
93.3%), as shown in Figure 3. Nine (60.0%) and 3 (20.0%) 
patients had stage III and stage II disease, respectively, while 
three patients (20.0%) had stage IV disease for supraclavic-
ular or abdominal lymph nodes. The most common clinical 
symptom was difficulty in swallowing (n = 15, 100%). Four 
patients (26.7%) experienced chest and back pain. Five cases 
(33.3%) were reported as squamous cell carcinoma on biopsy 
histopathological examination, but all patients were confirmed 
to have carcinosarcoma or spindle cell carcinoma on postop-
erative pathology.

Patient characteristics are shown in Table 2 when considering 
the data from the literature review. The median age at diagnosis 
was 63 years (range: 39–89 years). Most of the patients were 
men, with a protruding mass in the middle of the esophagus. As

Figure 2. Endoscopic appearance of the esophageal tumor. (A) Esophagoscopy reveals a huge mass with an irregular surface occupying the esophageal lumen of the thoracic esophagus. (B) Esophageal ultrasonography reveals that the lesions are mainly located in the mucosal layer and submucosa, some layers are closely related to the muscularis propria and the boundary is unclear, the adventitia is intact, and the lymph nodes beside the esophagus are observed.
shown in Figure S1, Supplemental Digital Content, http://links.lww.com/MD/H667, the most common clinical symptom was difficulty swallowing (72.7%). Except for the depth of infiltration and lymph node involvement, the main clinical characteristics of the two groups were similar.

3.2. Treatments and efficacy evaluation

In the curative/neoadjuvant RT group, 3 patients received curative RT alone or CRT for locally advanced disease or concurrent secondary primary tumors. One patient received concurrent paclitaxel combined with cisplatin, while the other patients received RT alone. After curative RT, all patients had reached partial remission in the post-treatment evaluation 1 to 3 months later. The patients in the adjuvant group underwent thoracoscopic radical esophagectomy with regional lymph node dissection following neoadjuvant CRT. One patient received concurrent S-1, whereas the other received RT alone. The postoperative pathological results showed that both patients underwent R0 resection, one of which had mild to moderate pathological response with Mandard TRG Grade 4 and decreased stage from clinical (c) stage III to yield-pathological (yp) stage II. The other patient, who was too weak to receive current CRT, had partial remission at 1 month after RT alone, but surgery was postponed because of epidemic coronaviruses. During the watch and wait period, the patient developed local recurrence after 4 months, received salvage chemotherapy based on etoposide combined with cisplatin, and underwent surgery 2 months later. The postoperative pathological results showed a mild pathological response with Mandard TRG Grade 4, but ypN0 (1 lymph node with severe pathological response).

3.3. Toxicities and survival outcomes

The side effects of RT alone and CRT mainly presented as grade 1 acute radiation esophagitis and myelosuppression, and grade 3 toxicity was only observed in 1 patient who received curative concurrent RT and intravenous chemotherapy. The symptoms were mostly relieved after treatment and the entire cohort completed the entire RT/CRT treatment course. All patients were monitored afterwards. After a median follow-up of 43.1 months (IQR, 14.6–41.1), the median time of OS and PFS were 40.2 months (95% confidence interval [CI], 13.1–67.3 months) and 19.0 months (95% CI, 13.9 months–24.1 months) for the entire cohort, 30.9 months (95% CI, 3.4–58.3 months) and 16.1 months (95% CI, 12.2–20.1 months) for adjuvant RT group. In the curative/neoadjuvant RT group, the median OS and PFS were not reached. Only 1 patient developed multiple failures during the study period, including local recurrence, regional recurrence, and oligo-bone metastasis, and received salvage CRT and immunotherapy but died from multiple distant metastases. One patient died of concurrent liver cancer with ECS under well-controlled conditions. The remaining 3 patients remained disease-free, as shown in Table 3.

Figure 4A–B shows that OS (hazard ratio [HR] 1.24, 95% CI, 0.23–6.79; \( P = .805 \)) and PFS (HR 0.59, 95% CI, 0.12–2.89; \( P = .519 \)) did not differ significantly between the 2 groups. When considering the literature view data in the final analysis, OS was also not different between the 2 groups, with the median survival time not reached and 40.1 months compared with the adjuvant RT group (HR 0.84, 95% CI, 0.25–2.81; \( P = .779 \)). PFS showed slight trend but not significant benefit in neoadjuvant/curative group, with the median PFS time of 36.0 months and 16.1 months compared with adjuvant RT group (HR 0.68, 95% CI, 0.26–1.76; \( P = .425 \)), as shown in Figure 4C–D.
The results showed that intensity-modulated RT or CRT with neoadjuvant or curative intent might be effective for downstaging primary tumors in advanced ECS patients with acceptable treatment-relative toxicity.

ECS, also known as spindle cell carcinoma (SpCC) (WHO classification 2000), is a rare type of neoplasm. It is composed of neoplastic squamous and sarcomatous spindle cells. In histological studies, the 2 components are mixed and often dominated by sarcomatoid components. Enrile et al proposed that sarcomatoid spindle cells are produced in response to cancer, Iwaya et al assumed that 2 separate stem cells are transformed independently or simultaneously into malignant cells to form a separate tumor, and Taniyama et al revealed that the individual components are derived from a single common progenitor cell. Ota et al postulated that these components originated from a single clone of granulocyte colony-stimulating factor (G-CSF), which was detected in both squamous cell carcinoma cells and sarcoma cells. The current concept refers to earlier reports that carcinosarcoma could arise from cells of epithelial origin. Chino et al found that the general type of ECS is related to the main components of the tumor. When the sarcoma component is the main component, it presents as polypoid type, and when it is dominated by carcinomatous components, it is mostly ulcerative.

Clinically, the ECS is characterized by rapid growth. Akagi et al reported that the doubling time of ECS is approximately half that of esophageal carcinoma. However, lesions typically demonstrate a polypoid growth pattern that spreads superficially. Because of intraluminal growth, patients with ECS manifest symptoms of dysphagia relatively early and the prognosis of ECS appears to be better than that of other esophageal malignancies.

A standard curative local treatment for ECS, except for surgery, has not been established because of the small number of reports. However, RT is also an option for patients with unresectable tumors or those who cannot tolerate surgery.

| Table 2 | Characteristics of the esophageal carcinomsarcoma patients received neoadjuvant/definitive and adjuvant radiation treatment |
|-----------------------------|---------------------------------------------------------------|
| Variables                 | Curative/neoadjuvant RT group (N = 15) (%) | Adjuvant RT group (N = 10), (%) |
| Age (yrs, range)           | 66 (39–89) | 64 (49–89) | 54 (39–66) | .046 |
| Sex                       | 21 (84.0) | 11 (73.3) | 10 (100.0) | .125 |
| Location of esophagus      | 4 (16.0) | 4 (26.7) | 0 (0.0) | .605 |
| Stage                     | 6 (24.0) | 5 (33.3) | 6 (60.0) | .036 |
| Depth of infiltration      | 6 (24.0) | 4 (26.7) | 2 (20.0) | .023 |
| Stage                     | 5 (20.0) | 4 (26.7) | 1 (10.0) | .129 |
| Treatments                | 2 (8.0) | 1 (6.7) | 1 (10.0) | 1.000 |
| Surgery + adjuvant RT/CRT | 7 (28.0) | 6 (40.0) | 1 (10.0) | 1.000 |
| Neoadjuvant RT/CRT + surgery | 12 (48.0) | 8 (53.3) | 4 (40.0) | 1.000 |
| Curative CRT/RT alone     | 11 (44.0) | 5 (33.3) | 2 (20.0) | 1.000 |

CRT = chemoradiotherapy, N = number, RT = radiation treatment.

| Table 3 | Clinical, demographic presenting features and clinical outcomes of the patients received curative/neoadjuvant radiotherapy |
|-------------|----------------------------------------------------------------------------------------------------------------------------------|
| Case Overview | Endoscopic findings | Biopsy pathological diagnosis | Clinical stage | Treatments | Regimens | Pathological stage | Side-effects | PFS (m) | OS |
| 1 70 YO, M Ulcerating | Spindle cell carcinoma | III (cT3N1M0) | CCRT + surgery | S-1 + 44.94 Gy | II (pT2N0M0) | Grade 1 | 37.4 | 37.4 mo alive |
| 2 49 YO, M Protruding | Carcinomsarcoma | IVB (cT4N1M1b) | CCRT | TP + 59.92 Gy | - | Grade 3 | 19.0 | 33.4 mo alive |
| 3 55 YO, M Protruding | Carcinomsarcoma | IVB (cT3N1M1b) | RT alone | 59.68 Gy | - | Grade 1 | 4.9 | 12.0 mo dead |
| 4 63 YO, M Protruding | Spindle cell carcinoma | III (cT3N2M0) | RT alone | 59.92 Gy | - | Grade 1 | 6.3 | 6.3 mo dead |
| 5 62 YO, M Protruding | Spindle cell carcinoma | I (cT1N1M0) | RT + salvage CT + surgery | 47.08 Gy + EP | - | Grade 1 | 22.7 | 22.7 mo alive |

CCRT = concurrent chemoradiotherapy, CT = chemotherapy, EP = etoposide + cisplatin, M = male, mo = months, OS = overall survival, PFS = progression-free survival, PR = partial response, RT = radiotherapy, S-1 = tegafur, TP = paclitaxel liposome + nedaplatin, YO = years old.

4. Discussion

The results showed that intensity-modulated RT or CRT with neoadjuvant or curative intent might be effective for downstaging primary tumors in advanced ECS patients with acceptable treatment-relative toxicity.

ECS, also known as spindle cell carcinoma (SpCC) (WHO classification 2000), is a rare type of neoplasm. It is composed of neoplastic squamous and sarcomatous spindle cells. In histological studies, the 2 components are mixed and often dominated by sarcomatoid components. Enrile et al proposed that sarcomatoid spindle cells are produced in response to cancer, Iwaya et al assumed that 2 separate stem cells are transformed independently or simultaneously into malignant cells to form a separate tumor, and Taniyama et al revealed that the individual components are derived from a single common progenitor cell. Ota et al postulated that these components originated from a single clone of granulocyte colony-stimulating factor (G-CSF), which was detected in both squamous cell carcinoma cells and sarcoma cells. The current concept refers to earlier reports that carcinosarcoma could arise from cells of epithelial origin. Chino et al found that the general type of ECS is related to the main components of the tumor. When the sarcoma component is the main component, it presents as polypoid type, and when it is dominated by carcinomatous components, it is mostly ulcerative.

Clinically, the ECS is characterized by rapid growth. Akagi et al reported that the doubling time of ECS is approximately half that of esophageal carcinoma. However, lesions typically demonstrate a polypoid growth pattern that spreads superficially. Because of intraluminal growth, patients with ECS manifest symptoms of dysphagia relatively early and the prognosis of ECS appears to be better than that of other esophageal malignancies.

A standard curative local treatment for ECS, except for surgery, has not been established because of the small number of reports. However, RT is also an option for patients with unresectable tumors or those who cannot tolerate surgery.
Figure 4. Kaplan–Meier analysis comparing survival stratified by radiation groups in the single institution cohort: overall survival (A) and progression-free survival (B). Kaplan–Meier analysis comparing survival stratified by radiation groups in the entire cohort: overall survival (C) and progression-free survival (D).
The clinical outcomes of RT alone and CRT have mostly been reported with postoperative or palliative intent.[22,24] Several studies listed in Table 1 have reported RT alone and CRT to be effective against esophageal carcinoma, which might be useful for reducing the tumor volume in esophageal carcinosarcoma; however, it is unknown whether it can cure the malignancy. Several studies have reported that CRT or RT alone with 40 Gy is effective against ECS along with surgery.[25] Appropriate RT prescriptions were inconsistent for treatments with curative intent. Kimura et al.[26] reported that palliative radiotherapy alone (45 Gy/15 f) achieved complete pathological response (pCR) in an 89 years old patient with a tumor diameter (T2N0M0) of 80 mm. However, the results of the study by Hameed et al showed a progressive disease response after 110 Gy RT with concurrent DDP.[27] This may be explained by improvements in RT technology. Patients develop severe complications after high-dose two-dimensional or three-dimensional conformal radiotherapy. Currently, however, IMRT not only effectively protects organs at risk,[28] but also improves survival outcomes.[29] From the most common point of view, 50 Gy was mostly used in western countries,[30] while 60 Gy was still the curative RT prescription for unresectable or inoperable ECS in Asian,[31] similar to common EC. Our results showed that RT and CRT were relatively sensitive and effective for ECS treatment. OS and PFS did not differ significantly between the curative/neoadjuvant and adjuvant groups and were similar to those in previous reports.[22]

A platinum-based chemotherapy regimen was used according to previous experience of treating EC.[32] In most reported cases, a combination of S-FU and DDP (FP) was utilized as the conventional chemotherapeutic component, such as ESCC, and patients could benefit from preoperative therapy.[33] For patients who did not tolerate the prolonged hospitalization needed for fractionated delivery of intravenous S-FU, the drug was replaced with S-1, an oral derivative of tegafur, which is known to be active against the squamous carcinoma component. Concurrent RT with S-1 has been proven to be effective and tolerable in patients with EC.[14,15] Moreover, docetaxel-based chemotherapy targeting sarcomatous components is currently used in several areas, such as bone, soft tissue, and gynecological sarcomas, and has shown favorable response rates.[16,37] Thus, chemotherapy that is effective for both carcinomatous[38] and sarcomatous components may be a rational option for preoperative chemotherapy in patients with ECS. Several studies have shown that chemotherapy regimens including paclitaxel, such as docetaxel, cisplatin, and 5-fluorouracil (DCF),[20,21] have good efficacy for preoperative chemotherapy.

Although our study showed promising results with RT treatment in patients with locally advanced ECS, some limitations should be addressed. This was a retrospective study with a small database that had inherent biases despite our effort to narrow down the inclusion criteria and consider the data of the literature review. Further research with a larger sample size is needed to validate this reliability. These findings suggest that preoperative intensity-modulated RT or CRT may be effective in downstaging the primary tumor in patients with advanced ECS. This may provide patients who cannot undergo surgical resection with adequate local control and longer survival. Treatment-related toxicity was acceptable.

5. Conclusion

These findings suggest that preoperative intensity-modulated RT or CRT may be effective in downstaging the primary tumor in patients with advanced ECS. It may provide patients who cannot undergo surgical resection with adequate local control and probably longer survival. The treatment-relative toxicity was acceptable.

Acknowledgments

The authors would like to thank our patients and their families for participating in this study and for their ethical approval.

Author contributions

Conceptualization: Nan Bi, Luhua Wang.

Data curation: Wenqing Wang.

Formal analysis: Siran Yang.

Funding acquisition: Nan Bi.

Investigation: Wenqing Wang, Zefen Xiao, Dongfu Chen, Jun Liang, Jima Lu, Jianyang Wang, Xin Wang, Jingbo Wang, Yong Yang, Ningning Lu, Hongxing Zhang.

Methodology: Wenqing Wang.

Project administration: Zongmei Zhou, Qinfu Feng, Zefen Xiao, Dongfu Chen, Jun Liang, Jima Lu, Jianyang Wang, Xin Wang, Jingbo Wang, Yong Yang, Ningning Lu, Hongxing Zhang.

Resources: Wenqing Wang, Zongmei Zhou, Qinfu Feng, Zefen Xiao, Dongfu Chen, Jun Liang, Jima Lu, Jianyang Wang, Xin Wang, Jingbo Wang, Yong Yang, Ningning Lu, Hongxing Zhang.

Software: Siran Yang.

Supervision: Luhua Wang.

Validation: Nan Bi.

Visualization: Siran Yang.

Writing – original draft: Siran Yang.

Writing – review & editing: Nan Bi.

References

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

[2] Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016. J Natl Cancer Center. 2022;2:1–9.

[3] Virchow R. Die Krankhaften Geschwulste, Geschwuiste. A Hirshward. 1858.

[4] Watanabe M, Tachimori Y, Oyama T, et al. Comprehensive registry of esophageal cancer in Japan, 2013. Esophagus. 2021;18:1–24.

[5] Au JT, Sugiyama G, Wang H, et al. Carcinosarcoma of the oesophagus – a rare mixed type of tumor. J Surg Case Rep. 2010;2010:7.

[6] Iyomasa S, Kato H, Tachimori Y, et al. Carcinosarcoma of the esophagus: a twenty-case study. Jpn J Clin Oncol. 1990;20:99–106.

[7] Wang L, Lin Y, Long H, et al. Esophageal carcinosarcoma: a unique entity with a better prognosis. Ann Surg Oncol. 2013;20:997–1004.

[8] Cavallin F, Scarpa M, Aliferi R, et al. Esophageal carcinosarcoma: management and prognosis at a single Italian series. Anticancer Res. 2014;34:7455–9.

[9] Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinico-pathological correlations. Cancer. 1994;73:680–6.

[10] Hamilton SR, Aaltoinen LA. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System. Lyon: International Agency for Research on Cancer (IARC) Press; 2000.

[11] Emre FF, De Jesus PO, Bakst AA, et al. Pseudosarcoma of the esophagus (polyloid carcinoma of esophagus with pseudosarcomatous features). Cancer. 1973;31:1197–202.

[12] Iwata Y, Maesawa C, Tamura G, et al. Esophageal carcinosarcoma: a genetic analysis. Gastroenterology. 1997;113:973–7.

[13] Taniyama K, Sasaki N, Muki T, et al. Carcinosarcomas of the esophagus. Pathol Int. 1995;45:297–302.

[14] Ota S, Kato A, Kobayashi H, et al. Monoclonal origin of an esophageal carcinosarcoma producing granulocyte-colony stimulating factor: a case report. Cancer. 1998;82:2102–11.

[15] Chino O, Kijima H, Shimada H, et al. Clinicopathological studies of esophageal carcinosarcoma: analyses of its morphological characteristics using endoscopic, histological, and immunohistochemical procedures. Endoscopy. 2000;32:706–11.

[16] Matsutani T, Nomura T, Hagiwara N, et al. A case of carcinosarcoma of the esophagus detected on fluorodeoxyglucose positron emission tomography. J Nippon Med Sch. 2014;81:401–5.

[17] Akagi I, Miyashita M, Makino H, et al. So-called carcinosarcoma of the esophagus: report of a case. J Nippon Med Sch. 2008;75:171–4.
[18] Ji F, Xu YM, Xu CF. Endoscopic polypectomy: a promising therapeutic choice for esophageal carcinosarcoma. World J Gastroenterol. 2009;15:3448–50.

[19] Madan AK, Long AE, Weldon CB, et al. Esophageal carcinosarcoma. J Gastrointest Surg. 2001;5:414–7.

[20] Yoshimoto T, Kobayashi S, Kanetaka K, et al. Preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal carcinosarcoma: a case report and review of the literature. Surg Case Rep. 2018;4:18.

[21] Hashimoto M, Kitagami H, Niwa H, et al. Prognosis and prognostic factors of esophageal spindle cell carcinoma treated by esophagectomy: a retrospective single-institution analysis. Esophagus. 2019;16:292–9.

[22] Zhang B, Xiao Q, Yang D, et al. Spindle cell carcinoma of the esophagus: a multicenter analysis in comparison with typical squamous cell carcinoma. Medicine (Baltim). 2016;95:e4768.

[23] Li P, Li Y, Zhang C, et al. Clinicopathological and prognostic characteristics of esophageal spindle cell squamous cell carcinoma: an analysis of 43 patients in a single center. Front Oncol. 2021;11:564270.

[24] Sanada Y, Hihara J, Yoshida K, et al. Esophageal carcinosarcoma with intramural metastasis. Dis Esophagus. 2006;19:119–31.

[25] Ogasawara N, Tamura Y, Funaki Y, et al. Rapidly growing esophageal carcinosarcoma reduced by neoadjuvant radiotherapy alone. Case Rep Gastroenterol. 2014;8:227–34.

[26] Kimura K, Hayashi Y, Otani K, et al. Esophageal carcinosarcoma that disappeared pathologically by palliative radiotherapy alone. Clin J Gastroenterol. 2019;12:247–53.

[27] Hameed H, Khan YL. Metastasis of carcinosarcoma of oesophagus to gastrostomy site. Br J Oral Maxillofac Surg. 2009;47:643–4.

[28] Chen NB, Qiu B, Zhang J, et al. Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy in definitive chemoradiotherapy for cervical esophageal squamous cell carcinoma: comparison of survival outcomes and toxicities. Cancer Res Treat. 2020;52:31–40.

[29] Li CC, Chen CY, Chien CR. Comparison of intensity-modulated radiotherapy vs 3-dimensional conformal radiotherapy for patients with non-metastatic esophageal squamous cell carcinoma receiving definitive concurrent chemoradiotherapy: a population-based propensity-score-matched analysis. Medicine (Baltim). 2018;97:e10928.

[30] Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20:1167–74.

[31] Nakao E, Iijima S, Tsujimura N, et al. A case of carcinosarcoma of the esophagus treated with chemoradiotherapy. Gan To Kagaku Ryoho. 2015;42:1905–7.

[32] Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomised trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999;281:1623–7.

[33] Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68–74.

[34] Ji Y, Du X, Zhu W, et al. Efficacy of concurrent chemoradiotherapy with S-1 vs radiotherapy alone for older patients with esophageal cancer: a multicenter randomized phase 3 clinical trial. JAMA Oncol. 2021;7:1459–66.

[35] Cho SH, Shim HJ, Lee SR, et al. Concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer. Dis Esophagus. 2008;21:697–703.

[36] Takahashi M, Komine K, Imai H, et al. Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis. PLoS One. 2017;12:e0176972.

[37] Choi Y, Yun MS, Lim SH, et al. Gemcitabine and docetaxel combination for advanced soft tissue sarcoma: a nationwide retrospective study. Cancer Res Treat. 2018;50:175–82.

[38] Chen Y, Ye J, Zhu Z, et al. Comparing paclitaxel plus fluorouracil versus cisplatin plus fluorouracil in chemoradiotherapy for locally advanced esophageal squamous cell cancer: a randomized, multicenter, phase III clinical trial. J Clin Oncol. 2019;37:1695–703.